GTG — Genetic Technologies Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Genetic Technologies, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
C2020 June 30th | C2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.01 | 0.121 | 6.79 | 8.69 | 7.66 |
Cost of Revenue | |||||
Gross Profit | -0.092 | -0.05 | 3.78 | 4.35 | 3.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6.29 | 7.52 | 14.4 | 21 | 19.6 |
Operating Profit | -6.28 | -7.4 | -7.57 | -12.3 | -11.9 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.29 | -7.08 | -7.16 | -11.9 | -12 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.29 | -7.08 | -7.13 | -11.8 | -12 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.29 | -7.08 | -7.13 | -11.8 | -12 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.29 | -7.08 | -7.13 | -11.8 | -12 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.151 | -0.082 | -0.074 | -0.098 | -0.077 |